Tajiri key facts
as of Oct 2026- Developer of anti-cancer medical solutions intended to address drug resistance and urgent clinical needs through next-generation small-molecule therapies.
- Tajiri is valued at approximately $145.6M as of Oct 2026 (last reported valuation).
- It has raised $85.8M; the latest was Secondary Transaction - Private in Sep 2025.
- Notable investors include Shenzhen Capital Group, Oriental Fortune Capital, CDH Investments, SEEDS Capital, Hongtai Capital Holdings — 12 tracked in total.
- Status: Privately Held (backing).
Tajiri's last reported valuation, Apr 2020. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Tajiri: the Monday email on marks, rounds and moves
Tajiri funding rounds
No funding rounds for Tajiri are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Tajiri
12+Membership and data by Private Market View
Tajiri valuation
Tajiri's last reported valuation was $146 million in Apr 2020. No priced round, secondary trade or fund mark has surfaced since.
Tajiri investors
12 investors are on record for Tajiri, including Shenzhen Capital Group, Oriental Fortune Capital, CDH Investments and SEEDS Capital. By type, the record holds 4 venture capital firms and 1 private equity firm.
About Tajiri
Developer of anti-cancer medical solutions intended to address drug resistance and urgent clinical needs through next-generation small-molecule therapies. The company offers drug resistance in cancer treatment and innovative medicines for more effective cancer treatment, thereby enabling them to overcome resistance to existing therapies, reduce treatment toxicity, and achieve more effective cancer management.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2014
- Employees
- 72
- Website
- tjrbiosciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.